BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang H, Rao B, Lou J, Li J, Liu Z, Li A, Cui G, Ren Z, Yu Z. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:55. [PMID: 32117981 DOI: 10.3389/fcell.2020.00055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Nie X, Tian Z, Chen D, Chen X, Zeng Q, Xu X. Single-domain antibodies for radio nuclear imaging and therapy of esophageal squamous cell carcinoma: a narrative review. Journal of Bio-X Research 2020;3:135-43. [DOI: 10.1097/jbr.0000000000000074] [Reference Citation Analysis]
2 El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Abulkhair HS, Eissa IH. New quinoxalin-2(1H)-one-derived VEGFR-2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies. Arch Pharm (Weinheim) 2022;:e2200048. [PMID: 35437829 DOI: 10.1002/ardp.202200048] [Reference Citation Analysis]
3 Eso Y. MET amplification as a potential therapeutic target against hepatocellular carcinoma. Hepatol Res 2021;51:1093-4. [PMID: 34724292 DOI: 10.1111/hepr.13702] [Reference Citation Analysis]
4 Lu G, Li X, Zhang J, Xu Q. Molecular insight into the affinity, specificity and cross-reactivity of systematic hepatocellular carcinoma RALT interaction profile with human receptor tyrosine kinases. Amino Acids 2021;53:1715-28. [PMID: 34618235 DOI: 10.1007/s00726-021-03083-8] [Reference Citation Analysis]
5 Meurer L, Ferdman L, Belcher B, Camarata T. The SIX Family of Transcription Factors: Common Themes Integrating Developmental and Cancer Biology. Front Cell Dev Biol 2021;9:707854. [PMID: 34490256 DOI: 10.3389/fcell.2021.707854] [Reference Citation Analysis]
6 Karmacharya U, Guragain D, Chaudhary P, Jee JG, Kim JA, Jeong BS. Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma. Int J Mol Sci 2021;22:9685. [PMID: 34575841 DOI: 10.3390/ijms22189685] [Reference Citation Analysis]
7 Li Q, Sun M, Wang M, Feng M, Yang F, Li L, Zhao J, Chang C, Dong H, Xie T, Chen J. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci 2021;112:1695-706. [PMID: 33605517 DOI: 10.1111/cas.14861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol 2021;12:731527. [PMID: 34804015 DOI: 10.3389/fimmu.2021.731527] [Reference Citation Analysis]
9 Li H. Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis 2021:S1590-8658(21)00375-3. [PMID: 34344577 DOI: 10.1016/j.dld.2021.07.006] [Reference Citation Analysis]
10 Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer 2021. [PMID: 34400801 DOI: 10.1038/s41416-021-01453-3] [Reference Citation Analysis]
11 El-Adl K, Ibrahim MK, Khedr F, Abulkhair HS, Eissa IH. Design, synthesis, docking, and anticancer evaluations of phthalazines as VEGFR-2 inhibitors. Arch Pharm (Weinheim) 2021;:e2100278. [PMID: 34596910 DOI: 10.1002/ardp.202100278] [Reference Citation Analysis]
12 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Reference Citation Analysis]
13 Wang L, Han H, Wang Z, Shi L, Yang M, Qin Y. Targeting the Microenvironment in Esophageal Cancer. Front Cell Dev Biol 2021;9:684966. [PMID: 34513829 DOI: 10.3389/fcell.2021.684966] [Reference Citation Analysis]
14 Alimoradi N, Sharqi M, Firouzabadi D, Sadeghi MM, Moezzi MI, Firouzabadi N. SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease. Virol J 2022;19. [DOI: 10.1186/s12985-022-01782-6] [Reference Citation Analysis]
15 Junren C, Xiaofang X, Huiqiong Z, Gangmin L, Yanpeng Y, Xiaoyu C, Yuqing G, Yanan L, Yue Z, Fu P, Cheng P. Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review. Front Pharmacol 2021;12:660757. [PMID: 33935784 DOI: 10.3389/fphar.2021.660757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 He Q, Lin Z, Wang Z, Huang W, Tian D, Liu M, Xia L. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 2020;39:7279-95. [PMID: 33046796 DOI: 10.1038/s41388-020-01500-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Briones-Orta MA, Delgado-Coello B, Gutiérrez-Vidal R, Sosa-Garrocho M, Macías-Silva M, Mas-Oliva J. Quantitative Expression of Key Cancer Markers in the AS-30D Hepatocarcinoma Model. Front Oncol 2021;11:670292. [PMID: 34737944 DOI: 10.3389/fonc.2021.670292] [Reference Citation Analysis]
18 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
19 Sasaki N, Toyoda M, Ishiwata T. Gangliosides as Signaling Regulators in Cancer. Int J Mol Sci 2021;22:5076. [PMID: 34064863 DOI: 10.3390/ijms22105076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Topel H, Bağırsakçı E, Yılmaz Y, Güneş A, Bağcı G, Çömez D, Kahraman E, Korhan P, Atabey N. High glucose induced c-Met activation promotes aggressive phenotype and regulates expression of glucose metabolism genes in HCC cells. Sci Rep 2021;11:11376. [PMID: 34059694 DOI: 10.1038/s41598-021-89765-5] [Reference Citation Analysis]
21 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
22 Zhang Y, Liang B, Song X, Wang H, Evert M, Zhou Y, Calvisi DF, Tang L, Chen X. Loss of Apc Cooperates with Activated Oncogenes to Induce Liver Tumor Formation in Mice. Am J Pathol 2021;191:930-46. [PMID: 33545120 DOI: 10.1016/j.ajpath.2021.01.010] [Reference Citation Analysis]
23 Bhave S, Ho HK. Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1776. [PMID: 34944593 DOI: 10.3390/biomedicines9121776] [Reference Citation Analysis]
24 El-Adl K, El-Helby AA, Ayyad RR, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Eissa IH. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors. Bioorg Med Chem 2021;29:115872. [PMID: 33214036 DOI: 10.1016/j.bmc.2020.115872] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
25 Xu R, Liu X, Li A, Song L, Liang J, Gao J, Tang X. c-Met up-regulates the expression of PD-L1 through MAPK/NF-κBp65 pathway. J Mol Med (Berl) 2022. [PMID: 35122106 DOI: 10.1007/s00109-022-02179-2] [Reference Citation Analysis]
26 Yang X, Liao HY, Zhang HH. Roles of MET in human cancer. Clin Chim Acta 2021;525:69-83. [PMID: 34951962 DOI: 10.1016/j.cca.2021.12.017] [Reference Citation Analysis]
27 Yu J, Xia X, Dong Y, Gong Z, Li G, Chen GG, Lai PBS. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling. Theranostics 2021;11:2123-36. [PMID: 33500715 DOI: 10.7150/thno.49368] [Reference Citation Analysis]
28 Fu J, Su X, Li Z, Deng L, Liu X, Feng X, Peng J. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene 2021;40:4625-51. [PMID: 34145400 DOI: 10.1038/s41388-021-01863-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Tang Y, Xu H, Dai Y, Wang F, Huang W, Liu P, Gu Y. A novel peptide targeting c-Met for hepatocellular carcinoma diagnosis. J Mater Chem B 2021;9:4577-86. [PMID: 34047746 DOI: 10.1039/d1tb00408e] [Reference Citation Analysis]
30 Sun X, Zhan M, Sun X, Liu W, Meng X. C1GALT1 in health and disease. Oncol Lett 2021;22:589. [PMID: 34149900 DOI: 10.3892/ol.2021.12850] [Reference Citation Analysis]
31 Yang T, Huo J, Xu R, Su Q, Tang W, Zhang D, Zhu M, Zhan Y, Dai B, Zhang Y. Selenium sulfide disrupts the PLAGL2/C-MET/STAT3-induced resistance against mitochondrial apoptosis in hepatocellular carcinoma. Clin Transl Med 2021;11:e536. [PMID: 34586726 DOI: 10.1002/ctm2.536] [Reference Citation Analysis]
32 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Reference Citation Analysis]
33 El Darsa H, El Sayed R, Abdel-Rahman O. MET Inhibitors for the Treatment of Gastric Cancer: What's Their Potential? J Exp Pharmacol 2020;12:349-61. [PMID: 33116950 DOI: 10.2147/JEP.S242958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
34 Farzaneh Z, Vosough M, Agarwal T, Farzaneh M. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches. Cancer Cell Int 2021;21:208. [PMID: 33849569 DOI: 10.1186/s12935-021-01924-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wei ZQ, Zhang YW. Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit. Chin Med J (Engl) 2021;134:2275-86. [PMID: 34593696 DOI: 10.1097/CM9.0000000000001767] [Reference Citation Analysis]
36 Khedr F, Ibrahim MK, Eissa IH, Abulkhair HS, El-Adl K. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations. Arch Pharm (Weinheim) 2021;354:e2100201. [PMID: 34411344 DOI: 10.1002/ardp.202100201] [Reference Citation Analysis]
37 Álvarez-Mercado AI, Caballeria-Casals A, Rojano-Alfonso C, Chávez-Reyes J, Micó-Carnero M, Sanchez-Gonzalez A, Casillas-Ramírez A, Gracia-Sancho J, Peralta C. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 2021;9:1158. [PMID: 34572344 DOI: 10.3390/biomedicines9091158] [Reference Citation Analysis]